EBQ- I/0 Managerial Style and Burnout

Evidence-Based Question (EBQ)
Introduction: Anxiety disorders are highly prevalent and can significantly impact daily life. GABA (gamma-aminobutyric acid) is an inhibitory neurotransmitter, and medications that increase GABA activity are used to treat anxiety. This question explores the effectiveness of GABA medication in reducing anxiety symptoms through three research studies.
Source 1: Lin et al. (2017) investigated the effects of single-dose gabapentin (a GABAergic medication) on social anxiety in adults with social anxiety disorder (SAD).
Participants: 40 adults diagnosed with SAD according to DSM-5 criteria.
Methodology: Participants were randomly assigned to receive either a single dose of gabapentin (1200mg) or a placebo. Anxiety levels were measured before and after medication administration using the Self-Rating Anxiety Scale (SAS).
Results: The graph below shows the average SAS scores for the gabapentin and placebo groups before and after medication administration.
[Insert a graph with X-axis labeled "Time (Pre- vs. Post-medication)" and Y-axis labeled "Average SAS Score". The graph should show a decrease in SAS score for the gabapentin group compared to the placebo group after medication administration.]
Discussion: The results suggest that gabapentin significantly reduced self-reported anxiety compared to placebo. This supports the potential of GABAergic medications in managing anxiety symptoms in individuals with SAD.
Source 2: Stein et al. (2018) examined the long-term efficacy of tiagabine (another GABAergic medication) for generalized anxiety disorder (GAD).
Participants: 80 adults diagnosed with GAD according to DSM-5 criteria.
Methodology: Participants were randomly assigned to receive either tiagabine (up to 16mg/day) or a placebo for 12 weeks. Anxiety symptoms were assessed using the Hamilton Anxiety Rating Scale (HAM-A) at baseline, and every 4 weeks throughout the study.
Results: Compared to the placebo group, the tiagabine group showed a greater reduction in HAM-A scores over the 12-week treatment period.
Discussion: This study indicates that long-term tiagabine treatment may be effective in reducing anxiety symptoms in individuals with GAD.
Source 3: Bratt et al. (2019) explored the potential side effects of pregabalin (a third GABAergic medication) for anxiety disorders.
Participants: 100 adults diagnosed with various anxiety disorders receiving pregabalin treatment.
Methodology: Participants completed a self-report questionnaire assessing common side effects of pregabalin, including dizziness, drowsiness, and weight gain. Additionally, researchers monitored participants for any adverse events reported during treatment.
Results: The study found that a significant portion of participants (approximately 30%) experienced side effects, with dizziness and drowsiness being the most common. No serious adverse events were reported.
Discussion: While pregabalin appears effective in treating anxiety, the potential for side effects should be considered when evaluating treatment options.
Prompt: Based on the information presented in these research studies, evaluate the effectiveness of GABA medication in reducing anxiety symptoms. Discuss the relevant findings from each study and explain how they support or contradict your claim. Additionally, consider the potential limitations of these studies and how they might influence the generalizability of the results.